Status:
COMPLETED
An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients
Lead Sponsor:
University of Colorado, Denver
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study designed to learn more about how COVID19 convalescent plasma works in patients with COVID19 compared to those patients who did not receive convalescent plasma treatment....
Detailed Description
This a prospective, observational cohort trial to evaluate safety, clinical outcomes, and SARS-CoV2 antibody responses in patients who were treated with anti-SARS-CoV-2 convalescent plasma under Expan...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19 SARS-CoV-2 RT-PCR testing.
- Patient treated with COVID19 convalescent plasma.
- Patient or surrogate designated decision maker is willing and able to provide written informed consent.
Exclusion
- Receipt of pooled immunoglobulin in past 30 days
- Contraindication to transfusion or history of prior reactions to transfusion blood products
Key Trial Info
Start Date :
April 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 20 2020
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT04471051
Start Date
April 30 2020
End Date
August 20 2020
Last Update
June 9 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
2
University of Colorado Hospital
Aurora, Colorado, United States, 80045
3
UCHealth Memorial Hospital North
Colorado Springs, Colorado, United States, 80920
4
Denver Health Medical Center
Denver, Colorado, United States, 80204